Affimed (AFMD) AI Stock Analysis

• Market Cap: $2.76M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 1.89
• Revenue Growth: -95.23%
• EPS Growth: -325.89%
• Country: US
• Employees: 76
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 15,227,463
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: -0.07
• Price to Book (P/B): 1.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $0.39
• Price Target Upside: 290.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 42 Neutral
• Price Target: ―

Affimed's overall stock score reflects its financial struggles, with declining revenue and increasing losses being major concerns. The stock is technically weak, and the valuation is challenging due to negative earnings. Positive aspects from the earnings call, such as strategic progress in clinical trials and reduced losses, provide some optimism but are outweighed by financial and operational challenges.

Positive Factors

Business Development

Management indicated that the three December datasets have enabled more substantive business development discussions.

Clinical Trial Developments

AFMD highlighted positive data from the LuminICE-203 study in cHL, showing significantly higher ORR compared to the only currently available option.

Partnership and Funding Opportunities

Upcoming presentation at a major oncology meeting presents a potential opportunity to attract partners or funding.

Negative Factors

Funding Challenges

The company is unlikely to secure funding to continue development of their three clinical programs.

Liquidity Concerns

Affimed discloses insufficient liquidity to operate for at least 12 months, shortening their operational runway.

Regulatory Hurdles

New leadership at the FDA reduces the probability of accelerated approval for Affimed's cell therapy.

Affimed Business Overview & Revenue Model

Company Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

How the Company Makes Money

Affimed primarily generates revenue through collaboration and license agreements with pharmaceutical companies, where they develop and commercialize their drug candidates. These agreements often include upfront payments, milestone payments based on the achievement of clinical, regulatory, and commercial milestones, and royalties on sales of commercialized products. Additionally, Affimed may receive funding from grants and research collaborations that support their development programs. Significant partnerships with larger pharmaceutical companies also contribute to their revenue by providing financial support and resources for advancing their therapeutic candidates through clinical trials.

Affimed Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	877.00K	8.28M	41.35M	40.37M	28.36M	21.39M
Gross Profit	877.00K	8.28M	41.35M	40.37M	28.36M	21.39M
EBITDA	-65.19M	-102.38M	-81.47M	-64.01M	-34.23M	-30.97M
Net Income	-69.97M	-105.94M	-86.00M	-57.52M	-41.37M	-32.37M
Balance Sheet
Total Assets	39.96M	97.16M	200.51M	225.13M	175.72M	112.36M
Cash, Cash Equivalents and Short-Term Investments	24.94M	72.90M	190.29M	197.63M	146.85M	104.14M
Total Debt	12.89M	19.35M	18.19M	18.69M	1.30M	3.19M
Total Liabilities	22.76M	39.35M	47.60M	89.18M	103.73M	73.69M
Stockholders Equity	17.20M	57.81M	152.91M	135.95M	71.99M	38.67M
Cash Flow
Free Cash Flow	-77.44M	-114.00M	-105.59M	-90.44M	-19.84M	-30.53M
Operating Cash Flow	-76.90M	-110.27M	-104.89M	-86.59M	-19.40M	-29.06M
Investing Cash Flow	19.68M	-36.06M	5.61M	-3.85M	8.01M	4.34M
Financing Cash Flow	714.00K	-6.22M	88.56M	133.58M	69.25M	26.04M

Affimed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
TXMD	47 Neutral	$13.66M	―	-7.72%	―	35.25%	81.05%
AFMD	42 Neutral	$2.76M	―	-151.46%	―	-95.23%	-325.89%
APRE	40 Underperform	$9.62M	―	-59.80%	―	157.63%	40.52%
ATHA	36 Underperform	$13.27M	―	-110.70%	―	―	18.61%
SPRB	35 Underperform	$3.06M	―	-135.33%	―	-51.32%	-1.76%
RNAZ	27 Underperform	$7.04M	―	-342.99%	―	―	99.64%